ArticleMicrobiology spectrum2022
Morganella morganii, an Emerging Cause of Bloodstream Infections.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- A systematic review and meta-analysis of the global prevalence of fluoroquinolone resistant Morganella morganii clinical isolates.Scientific reports · 2025Pooled it
- Genomic profiling ofMicrobiology spectrum · 2026Article
- One Health approach to characterize antimicrobial resistance inJAC-antimicrobial resistance · 2026Article
- Gut microbiota and serum metabolic profiles in patients with sepsis-induced cardiomyopathy and their association with the disease.Frontiers in cellular and infection microbiology · 2026Article
- Article
- Antimicrobial Resistance Profile and Longitudinal Trends ofSisli Etfal Hastanesi tip bulteni · 2026Article
- From Symbiont to Potential Carcinogenic Contributor: Examining the Pathogenic Evolution ofInfection and drug resistance · 2026Review
- Morganella morganii Bacteremia in an Immunocompetent 13-Year-Old Male: A Rare Pediatric Case.Cureus · 2025Article
- Article
- NewPHAGE (New Rochelle, N.Y.) · 2025Article
- Stuck between a rock and a hard place: heart failure with bilateral atrial appendage thrombi and disseminated intravascular coagulation-a case report.European heart journal. Case reports · 2025Article
- Clinical characteristics, specific resistance patterns, and molecular mechanisms of carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Investigation of co-existing bacteria in platelets by employing long-term culturomics and metagenomics.Frontiers in cellular and infection microbiology · 2025Article
- Influence of Urinary Urea Concentration on Hemolytic Activity and Cytotoxicity of Uropathogenic Morganella morganii Strain.Bulletin of experimental biology and medicine · 2024Article
- Article
- Tracing the possible evolutionary trends ofmSystems · 2024Article
- Isolation and Identification ofVeterinary sciences · 2024Article
- Genomic epidemiology and antimicrobial resistance ofFrontiers in cellular and infection microbiology · 2024Article
- Distribution diversity and expression regulation of class 1 integron promoters in clinical isolates ofFrontiers in microbiology · 2024Article
- Plasma metagenomics reveals regional variations of emerging and re-emerging pathogens in Chinese blood donors with an emphasis on human parvovirus B19.One health (Amsterdam, Netherlands) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although recent reports of extensively antibiotic-resistant strains have highlighted the importance of Morganella morganii as an emerging pathogen, the epidemiology of serious infections due to this organism is not well defined. The objective of this study was to determine the incidence, determinants, and outcomes of Morganella morganii bloodstream infections (BSIs). Retrospective, population-based surveillance for Morganella morganii BSIs was conducted in Queensland, Australia, in 2000 to 2019; 709 cases were identified, for an annual incidence of 9.2 cases per million population. Most cases were of community onset, with 280 (39.5%) community-associated cases and 226 (31.9%) health care-associated cases. Morganella morganii BSIs were rare in children and young adults, and the incidence increased markedly with advancing age. The most common foci of infection were skin and soft tissue (131 cases [18.5%]), genitourinary (97 cases [13.7%]), and intraabdominal (90 cases [12.7%]). Most patients (580 cases [81.8%]) had at least one comorbid medical illness, with diabetes mellitus (250 cases [35.3%]), renal disease (208 cases [29.3%]), and congestive heart failure (167 cases [23.6%]) being most prevalent. Resistance to one or more of quinolones, co-trimoxazole, aminoglycosides, or carbapenems was observed in 67 cases (9.5%), and this did not change significantly over the study. The 30-day all-cause case fatality rate was 21.2%, and increasing age, nonfocal infection, heart failure, dementia, and cancer were independently associated with increased risk of death. Morganella morganii BSIs are increasing in our population, and elderly male subjects and individuals with comorbidities are at highest risk. Although antibiotic resistance is not a major contributor to the current burden in Queensland, ongoing surveillance is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.